Towards liver-directed gene therapy for Crigler-Najjar syndrome

Current Gene Therapy

Volumn 9, Issue 2, 2009, Pages 72-82

  Miranda, Paula S Montenegro ^a   Bosma, Piter J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

AAV; Adenovirus; Bilirubin; Gunn rat; Lentivirus; Non viral vectors; Retrovirus; UGT1A1

Indexed keywords

ADENOVIRUS VECTOR; ASIALOGLYCOPROTEIN; BILIRUBIN; COLCHICINE; GLUCURONOSYLTRANSFERASE 1A1; LENTIVIRUS VECTOR; OLIGONUCLEOTIDE; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; TACROLIMUS;

BILIRUBIN BLOOD LEVEL; BILIRUBIN METABOLISM; CATALYSIS; CLINICAL TRIAL; CRIGLER NAJJAR SYNDROME; DISEASE MODEL; DISEASE SEVERITY; EX VIVO GENE TRANSFER; GENE EXPRESSION; GENE THERAPY; GILBERT DISEASE; GLUCURONIDATION; HEMOPHILIA; HUMAN; IN VIVO GENE TRANSFER; KERNICTERUS; NONHUMAN; NONVIRAL GENE THERAPY; PHOTOTHERAPY; PLASMID; REVIEW; VIRAL GENE THERAPY;

ANIMALS; BILIRUBIN; CRIGLER-NAJJAR SYNDROME; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER DISEASES; RATS;

ADENOVIRIDAE; ANIMALIA; LENTIVIRUS; RATTUS NORVEGICUS;

EID: 65949095203     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309787909508     Document Type: Review

References (98)

1. Crigler JF, Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics 1993; 10: 169-80.
2. Gunn CH. Hereditary acholuric jaundice. J Hered 1938; 29: 137-9
3. Bissell DM. Heme catabolism and bilirubin formation. In: Ostrow JD, Ed. Bile Pigments and Juandice. New York, Marcel Dekker 1986; pp. 133-56.
4. Fevery N, vanSteenbergen W, Sieg A, Muraca M. Pathophysiology of the hyperbilirubinemias. In: Taoloni N, Berk PD, Eds. Hepatic Transport and Bile Secretion. New York, Raven Press 1993; pp. 637-47.
5. Zucker SD, Goessling W, Zeidel ML, Gollan JL. Membrane lipid composition and vesicle size modulate bilirubin intermembrane transfer. Evidence for membrane-directed trafficking of bilirubin in the hepatocyte. J Biol Chem 1994; 269:19262-70.
6. Zucker SD, Goessling W, Gollan JL. Kinetics of bilirubin transfer between serum albumin and membrane vesicles. Insight into the mechanism of organic anion delivery to the hepatocyte plasma membrane. J Biol Chem 1995; 270: 1074-81.
7. Tiribelli C, Ostrow JD. New concepts in bilirubin chemistry, transport and metabolism: report of the Second International Bilirubin Workshop, April 9-11, 1992, Trieste, Italy. Hepatology 1993; 17: 715-36.
8. Paulusma CC, Kool M, Bosma PJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1993; 25: 1539-42.
9. Paulusma CC, Bosma PJ, Zaman GJ, et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996; 271: 1126-8.
10. Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol 1996; 38: 107-17.
11. Axelrod J, Schmid R, Hammaker L. A biochemical lesion in congenital, nonobstructive, non-haemolytic jaundice. Nature 1957; 180: 1426-7.
12. Schmid R, Axelrod J, Hammaker L, Swarm RL. Congenital jaundice in rats, due to a defect in glucuronide formation. J Clin Invest 1958; 37: 1123-30.
13. Lathe GH, Walker M. The synthesis of bilirubin glucuronide in animal and human liver. Biochem J 1958; 70: 705-12.
14. Arias IM, Gartner LM, Cohen M, Ezzer JB, Levi AJ. Chronic non-hemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity. Am J Med 1958; 47: 395-409.
15. Sinaasappel M, Jansen PL. The differential diagnosis of Crigler-Najjar disease, types 1 and 2, by bile pigment analysis. Gastroenterology 1958; 100: 783-9.
16. Ritter JK, Crawford JM, Owens IS. Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. J Biol Chem 1958; 266: 1043-7.
17. Ritter JK, Yeatman MT, Ferreira P,Owens IS. Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient. J Clin Invest 1958; 90: 150-5.
18. Ritter JK, Chen F, SheenYY, et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 1992; 267: 3257-61.
19. Bosma PJ, Chowdhury JR, Huang TJ, et al. Mechanisms of inherited deficiencies of multiple UDP-glucuronosyltransferase isoforms in two patients with Crigler-Najjar syndrome, type I. FASEB J 1992; 6: 2859-63.
20. Bosma PJ, Chowdhury NR, Goldhoorn BG, et al. Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology 1992; 15: 941-47.
21. Moghrabi N, Clarke DJ, Burchell B, Boxer M. Cosegregation of intragenic markers with a novel mutation that causes Crigler-Najjar syndrome type I: implication in carrier detection and prenatal diagnosis. Am J Hum Genet 1993; 53: 722-9.
22. Aono S, Yamada Y, Keino H, et al. Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II. Biochem Biophys Res Commun 1993; 197: 1239-44.
23. Labrune P, Myara A, Hadchouel M, et al. Genetic heterogeneity of Crigler-Najjar syndrome type I: a study of 14 cases. Hum Genet 1994; 94: 693-7.
24. Servedio V, d'Apolito M, Maiorano M, et al. Spectrum of UGT1A1 mutations in Crigler-Najjar(CN) syndrome patients: Identification of twelve novel alleles and genotype-phenotype correlation. Hum Mutat 1994; 25: 325.
25. Bosma PJ, Seppen J, Goldhoorn B, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 1994; 269: 17960-4.
26. Seppen J, Bosma PJ, Goldhoorn BG, et al. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 1994; 94: 2385-91.
27. Poddar B, Bharti B, Goraya J, Parmar VR. Kernicterus in a child with Crigler-Najjar syndrome type II. Trop Gastroenterol 2002; 23: 33-4.
28. Thapa BR, Yachha SK, Mehta S. Crigler-Najjar syndrome type II with kernicterus. Indian Pediatr 1987; 24: 680-3.
29. Cremer RJ, Perryman PW, Richard DH. Influence of light on the hyperbilirubinaemia of infants. Lancet 1958; 1: 1094-7.
30. Ostrow JD. Photocatabolism of labeled bilirubin in the congenitally jaundiced (Gunn) rat. J Clin Invest 1971; 50: 707-18.
31. Stoll MS. Phototherapy of jaundice. In: Ostrow JD, Ed. Bile Pigments and Jaundice. NewYork, Raven Press 1986; pp. 551-80.
32. Van de Veere C, Sinaasappel M, McDonagh AF, et al. Current therapy for Crigler-Najjar syndrome type 1: report of a world registry. Hepatology 1996; 24: 311-5.
33. Pett S, Mowat AP. Crigler-Najjar syndrome types I and II. Clinical experience--King's College Hospital 1972-1978. Phenobarbitone, phototherapy and liver transplantation. Mol Aspects Med 1987; 9: 473-82.
34. Whitington PF, Emond JC, Heffron T, Thistlethwaite JR. Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1. Lancet 1993; 342: 779-80.
35. Fox IJ, Chowdhury JR, Kaufman SS, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998; 338: 1422-6.
36. Lysy PA, Najimi M, Stephenne X, et al. Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives. World J Gastroenterol 2008; 14: 3464-70.
37. Wilke M, Bijma A, Timmers-Reker AJ, Scholte BJ, Sinaasappel M. Complementation of the genetic defect in Gunn rat hepatocytes in vitro by highly efficient gene transfer with cationic liposomes. Gene Ther 1997; 4: 1305-12.
38. Wu GY, Wu CH. Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988; 263: 14621-4.
39. Chowdhury NR, Hays RM, Bommineni VR, et al. Microtubular disruption prolongs the expression of human bilirubin-uridinediphosphoglucuronate-glucuronosyltransferase-1 gene transferred into Gunn rat livers. J Biol Chem 1996; 271: 2341-6.
40. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-7.
41. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-66.
42. Danko I, Jia Z, Zhang G. Nonviral gene transfer into liver and muscle for treatment of hyperbilirubinemia in the gunn rat. Hum Gene Ther 2004; 15: 1279-86.
43. Jia Z, Danko I. Single hepatic venous injection of liver-specific naked plasmid vector expressing human UGT1A1 leads to longterm correction of hyperbilirubinemia and prevention of chronic bilirubin toxicity in Gunn rats. Hum Gene Ther 2005; 16: 985-95.
44. Kren BT, Parashar B, Bandyopadhyay P, et al. Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotide. Proc Natl Acad Sci USA 1999; 96: 10349-54.
45. Taubes G. Gene therapy. The strange case of chimeraplasty. Science 2002; 298: 2116-20.
46. Taubes G. Gene therapy. Pioneering papers under the microscope. Science 2002; 298: 2118-9.
47. Raper SE, Yudkoff M, Chirmule N, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13: 163-75.
48. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004; 6(Suppl 1): S164-S171.
49. Askari FK, Hitomi Y, Mao M, Wilson JM Complete correction of hyperbilirubinemia in the Gunn rat model of Crigler-Najjar syndrome type I following transient in vivo adenovirus-mediated expression of human bilirubin UDP-glucuronosyltransferase. Gene Ther 1996; 3: 381-8.
50. Li Q, Murphree SS, Willer SS, Bolli R, French BA. Gene therapy with bilirubin-UDP-glucuronosyltransferase in the Gunn rat model of Crigler-Najjar syndrome type 1. Hum Gene Ther 1998; 9: 497-505.
51. Takahashi M, Ilan Y, Chowdhury NR, et al. Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. J Biol Chem 1996; 271: 26536-42.
52. Ilan Y, Attavar P, Takahashi M, et al. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. J Clin Invest 1996; 98: 2640-7.
53. Ilan Y, Sauter B, Chowdhury NR, et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 1998; 27: 1368-76.
54. Ilan Y, Jona VK, Sengupta K, et al. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Hepatology 1997; 26: 949-56.
55. Ilan Y, Droguett G, Chowdhury NR, et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 1997; 94: 2587-92.
56. Thummala NR, Ghosh SS, Lee SW, et al. A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridinediphosphoglucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome. Gene Ther 2002; 9: 981-90.
57. Segura MM, Alba R, Bosch A, Chillon M. Advances in helper-dependent adenoviral vector research. Curr Gene Ther 2008; 8: 222-35.
58. Toietta G, Mane VP, Norona WS, et al. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 2005 102: 3930-5.
59. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 2002; 13: 3-13.
60. Nguyen TH, Ferry N. Liver gene therapy: advances and hurdles. Gene Ther 2004; 11 (Suppl 1): S76-S84.
61. Ehrhardt A, Kay MA. Gutted adenovirus: a rising star on the horizon? Gene Ther 2005; 12: 1540-1.
62. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-7.
63. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2007; 7: 316-24.
64. Seppen J, Bakker C, de Jong B, et al. Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. Mol Ther 2006; 13: 1085-92.
65. McCarty DM, Fu H, Monahan PE, et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2006; 10: 2112-8.
66. Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854-9.
67. Barquinero J, Eixarch H, Perez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Ther 2004; 11 (Suppl 1): S3-S9.
68. Branchereau S, Ferry N, Myara A, et al. Correction of bilirubin glucuronyl transferase in Gunn rats by gene transfer in the liver using retroviral vectors. Chirurgie 1993; 119: 642-8.
69. Tada K, Chowdhury NR, Neufeld D, et al. Long-term reduction of serum bilirubin levels in Gunn rats by retroviral gene transfer in vivo. Liver Transpl Surg 1998; 4: 78-88.
70. Aubert D, Menoret S, Chiari E, et al. Cytotoxic immune response blunts long-term transgene expression after efficient retroviral-mediated hepatic gene transfer in rat. Mol Ther 2002; 5: 388-96.
71. Bellodi-Privato M, Aubert D, Pichard V, et al. Successful gene therapy of the Gunn rat by in vivo neonatal hepatic gene transfer using murine oncoretroviral vectors. Hepatology 2005; 42: 431-8.
72. Seppen J, van Til NP, van der Rijt R, et al. Immune response to lentiviral bilirubin UDP-glucuronosyltransferase gene transfer in fetal and neonatal rats. Gene Ther 2006; 13: 672-7.
73. Seppen J, van der Rijt R, Looije N, et al. Long-term correction of bilirubin UDPglucuronyltransferase deficiency in rats by in utero lentiviral gene transfer. Mol Ther 2003; 8: 593-9.
74. Brown BD, Venneri MA, Zingale A, Sergi SL, Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006; 12: 585-91.
75. De Geest BR, Van Linthout SA, Collen D. Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. Blood 2003; 101: 2551-6.
76. Nguyen TH, Aubert D, Bellodi-Privato M, et al. Critical assessment of lifelong phenotype correction in hyperbilirubinemic Gunn rats after retroviral mediated gene transfer. Gene Ther 2007; 14: 1270-7.
77. Nguyen TH, Bellodi-Privato M, Aubert D, et al. Therapeutic lentivirus-mediated neonatal in vivo gene therapy in hyperbilirubinemic Gunn rats. Mol Ther 2005; 12: 852-9.
78. van der Wegen P, Louwen R, Imam AM, et al. Successful treatment of UGT1A1 deficiency in a rat model of Crigler-Najjar disease by intravenous administration of a liver-specific lentiviral vector. Mol Ther 2006; 13: 374-81.
79. Brown BD, Cantore A, Annoni A, et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007; 110: 4144-52.
80. Qasim W, Gaspar HB, Thrasher AJ. Gene therapy for severe com bined immune deficiency. Exp Rev Mol Med 2004; 6: 1-15.
81. Overturf K, Al-Dhalimy M, Manning K, et al. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I. Hum Gene Ther 1998; 9: 295-304.
82. De Vree JM, Ottenhoff R, Bosma PJ, et al. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000; 119: 1720-30.
83. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6: 335-41.
84. Askari F, Hitomi E, Thiney M, Wilson JM. Retrovirus-mediated expression of HUG Br1 in Crigler-Najjar syndrome type I human fibroblasts and correction of the genetic defect in Gunn rat hepatocytes. Gene Ther 1995; 2: 203-8.
85. Kawashita Y, Guha C, Moitra R, et al. Hepatic repopulation with stably transduced conditionally immortalized hepatocytes in the Gunn rat. J Hepatol 2008; 49: 99-106.
86. Nguyen TH, Birraux J, Wildhaber B, et al. Ex vivo lentivirus transduction and immediate transplantation of uncultured hepatocytes for treating hyperbilirubinemic Gunn rat. Transplantation 2006; 82: 794-803.
87. Seppen J, Tada K, Ottenhoff R, et al. Transplantation of Gunn rats with autologous fibroblasts expressing bilirubin UDP-glucuronosyltransferase: correction of genetic deficiency and tumor formation. Hum Gene Ther 1997; 8: 27-36.
88. Strauss KA, Robinson DL, Vreman HJ, et al. Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur J Pediatr 2006; 165: 306-19.
89. Chalasani N, Chowdhury NR, Chowdhury JR, Boyer TD. Kernicterus in an adult who is heterozygous for Crigler-Najjar syndrome and homozygous for Gilbert-type genetic defect. Gastroenterology 1997; 112: 2099-103.
90. Hafkamp AM, Nelisse-Haak R, Sinaasappel M, Oude Elferink RP, Verkade HJ. Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial. Pediatr Res 2007; 62: 725-30.
91. Van der Veere C, Jansen PL, Sinaasappel M, et al. Oral calcium phosphate: a new therapy for Crigler-Najjar disease? Gastroenterology 1997; 112: 455-62.
92. Brodersen R, Friis-Hansen B, Stern L. Drug-induced displacement of bilirubin from albumin in the newborn. Dev Pharmacol Ther 1983; 6: 217-29.
93. Robards C, Brull SJ. The anesthetic implications of Crigler-Najjar syndrome. Anesth Analg 2007; 104: 435-6.
94. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3: 477-88.
95. Wu Z, Sun J, Zhang T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 2008; 16: 280-9.
96. Nathwani AC, Gray JT, McIntosh J, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 2007; 109: 1414-21.
97. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008; 28: 2303-4.
98. Goncalves MA, Holkers M, van Nierop GP, et al. Targeted chromosomal insertion of large DNA into the human genome by a fiber modified high-capacity adenovirus-based vector system. PLoS ONE 2008; 3: e3084.